BCRX

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -0.13
Percentage change -1.19	%

Peers: VRTX REGN IONS ALNY SRPT PTCT BMRN CRSP BLUE RARE

| Held by: VTI IWM XBI VXF VB IWO IBB VBK SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.26	Insider Own	4.19%	Shs Outstand	209.21M	Perf Week	3.46%
Market Cap	2.25B	Forward P/E	27.32	EPS next Y	0.39	Insider Trans	-0.08%	Shs Float	200.47M	Perf Month	21.47%
Income	-53.47M	PEG	-	EPS next Q	0.01	Inst Own	84.36%	Short Float	10.46%	Perf Quarter	24.85%
Sales	503.49M	P/S	4.47	EPS this Y	132.67%	Inst Trans	5.62%	Short Ratio	4.52	Perf Half Y	47.87%
Book/sh	-2.16	P/B	-	EPS next Y	180.11%	ROA	-11.28%	Short Interest	20.98M	Perf Year	73.67%
Cash/sh	1.41	P/C	7.62	EPS next 5Y	-	ROE	-	52W Range	5.92 - 11.11	Perf YTD	42.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	14.52%	ROI	-15.72%	52W High	-3.24%	Beta	1.11
Dividend TTM	-	Quick Ratio	2.88	Sales past 5Y	169.91%	Gross Margin	96.64%	52W Low	81.59%	ATR (14)	0.46
Dividend Ex-Date	-	Current Ratio	2.93	EPS Y/Y TTM	75.79%	Oper. Margin	6.59%	RSI (14)	64.20	Volatility	2.45% 5.46%
Employees	580	Debt/Eq	-	Sales Y/Y TTM	41.67%	Profit Margin	-10.62%	Recom	1.17	Target Price	16.58
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	100.06%	Payout	-	Rel Volume	0.69	Prev Close	10.88
Sales Surprise	13.89%	EPS Surprise	100.00%	Sales Q/Q	56.89%	Earnings	May 05 BMO	Avg Volume	4.64M	Price	10.75
SMA20	4.56%	SMA50	23.90%	SMA200	33.44%	Trades		Volume	3,215,035	Change	-1.19%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$20
Feb-25-25	Initiated	Wedbush	Outperform	$15
Nov-20-23	Resumed	JP Morgan	Overweight	$10
Sep-18-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$9 → $10
Aug-04-23	Upgrade	Jefferies	Hold → Buy	$11
Jul-13-23	Upgrade	BofA Securities	Neutral → Buy	$10
Feb-22-23	Upgrade	Needham	Hold → Buy	$14
Nov-02-22	Upgrade	Evercore ISI	In-line → Outperform	$14 → $16
Aug-05-22	Downgrade	Oppenheimer	Outperform → Perform
Aug-05-22	Downgrade	Evercore ISI	Outperform → In-line	$14
Apr-18-22	Downgrade	Barclays	Overweight → Equal Weight	$22 → $13
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral	$21 → $14
Dec-10-21	Initiated	Oppenheimer	Outperform	$16
Aug-06-21	Downgrade	Jefferies	Buy → Hold
Aug-03-21	Initiated	Cantor Fitzgerald	Overweight	$21
Mar-01-21	Initiated	Cowen	Outperform	$16
Sep-29-20	Resumed	JP Morgan	Overweight	$7
Jun-17-20	Initiated	BTIG Research	Neutral
May-05-20	Upgrade	Barclays	Equal Weight → Overweight	$7
Nov-15-19	Upgrade	BofA/Merrill	Neutral → Buy	$5 → $4

Show Previous Ratings

May-30-25 07:00AM	BioCryst Highlights Real-world Data Showing ORLADEYO (berotralstat) Consistently Reduces HAE Attacks Across All Ages (GlobeNewswire)
May-28-25 09:40AM	Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year? (Zacks)
May-27-25 07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
May-26-25 09:55AM	Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade (Zacks)
May-16-25 07:00AM	BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO (berotralstat) (GlobeNewswire)
09:40AM	Loading…
May-15-25 09:40AM	FDA awards BioCrysts Orladeyo NDA for paediatric HAE (Pharmaceutical Technology)
May-14-25 07:00AM	BioCryst Announces FDA Acceptance of NDA for ORLADEYO (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years (GlobeNewswire)
May-09-25 10:00AM	Best Momentum Stocks to Buy for May 9th (Zacks)
07:08AM	New Strong Buy Stocks for May 9th (Zacks)
May-08-25 12:20PM	Why BioCryst (BCRX) Might be Well Poised for a Surge (Zacks)
12:00PM	What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now? (Zacks)
09:55AM	Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect? (Zacks)
May-06-25 04:50AM	Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday (Insider Monkey) -6.89%
03:02AM	BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highlights: Strong ORLADEYO Sales ... (GuruFocus.com)
12:56AM	Q1 2025 BioCryst Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:05PM	Loading…
May-05-25 02:05PM	BioCryst: Strong Opportunity For A Double With A Proven Therapy (Seeking Alpha) +23.52%
12:54PM	BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:20AM	BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1 (Zacks)
07:00AM	BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-02-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-01-25 07:00AM	BioCryst Appoints Steve Frank to Board of Directors (GlobeNewswire)
Apr-30-25 10:01AM	Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
Apr-28-25 10:00AM	BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-21-25 07:00AM	BioCryst to Report First Quarter 2025 Financial Results on May 5 (GlobeNewswire)
Apr-10-25 05:21PM	How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry (Zacks) -5.32% +6.40%
Apr-04-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.82%
Apr-02-25 04:01PM	BioCryst to Present at Upcoming Investor Conference (GlobeNewswire)
Mar-06-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-25 09:13AM	Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now? (Insider Monkey)
10:30AM	Loading…
Feb-27-25 10:30AM	BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
Feb-26-25 09:55AM	Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher (Zacks)
09:55AM	Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know (Zacks)
Feb-25-25 02:28AM	Q4 2024 BioCryst Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:01AM	BioCryst Pharmaceuticals Inc (BCRX) Q4 2024 Earnings Call Highlights: Strong ORLADEYO Revenue ... (GuruFocus.com)
Feb-24-25 06:15PM	Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today (Motley Fool) -9.99%
04:30PM	BioCryst Pharmaceuticals (BCRX) Q4 2024 Earnings Call Transcript (Motley Fool)
08:10AM	BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:17AM	BioCryst: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones (GlobeNewswire)
06:00AM	BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to (GlobeNewswire)
Feb-19-25 07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-17-25 10:00AM	BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Feb-12-25 07:00AM	BioCryst Launches ORLADEYO (berotralstat) in Portugal (GlobeNewswire)
Feb-10-25 08:30AM	BioCryst to Present New ORLADEYO (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress (GlobeNewswire)
07:00AM	BioCryst to Report Fourth Quarter 2024 Financial Results on February 24 (GlobeNewswire)
Feb-04-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.17%
Jan-14-25 08:35AM	BioCryst price target raised to $12 from $10 at Evercore ISI (TipRanks) -8.83%
Jan-10-25 07:00AM	BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) (GlobeNewswire)
Jan-07-25 07:00AM	BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-04-24 04:15PM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.96%
Nov-18-24 02:00AM	BioCryst Launches ORLADEYO (berotralstat) in Ireland (GlobeNewswire)
Nov-06-24 07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire) +9.57%
Nov-05-24 07:29AM	BioCryst Announces Strong Q3 2024 Revenue Growth (TipRanks)
07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:32AM	Q3 2024 BioCryst Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
02:03AM	BioCryst Pharmaceuticals Inc (BCRX) Q3 2024 Earnings Call Highlights: Strong ORLADEYO Growth ... (GuruFocus.com)
Nov-04-24 02:30PM	BioCryst Pharmaceuticals (BCRX) Q3 2024 Earnings Call Transcript (Motley Fool) -12.81%
08:10AM	BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:06AM	BioCryst: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-24-24 08:00AM	BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO (berotralstat) (GlobeNewswire)
Oct-23-24 09:55AM	How Much Upside is Left in BioCryst (BCRX)? Wall Street Analysts Think 79.5% (Zacks)
Oct-21-24 07:00AM	BioCryst to Report Third Quarter 2024 Financial Results on November 4 (GlobeNewswire)
Oct-17-24 03:05PM	State Street Corp's Strategic Reduction in BioCryst Pharmaceuticals Holdings (GuruFocus.com)
Oct-14-24 07:00AM	BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO (berotralstat) (GlobeNewswire)
Oct-11-24 12:15PM	Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler? (Insider Monkey)
Oct-10-24 07:00AM	BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting (GlobeNewswire)
Oct-09-24 08:03AM	BioCryst Pharmaceuticals, Inc. (BCRX) Surpasses Revenue Expectations by $11 Million in Q2 (Insider Monkey)
Oct-07-24 12:00PM	BioCryst (BCRX) Upgraded to Buy: Here's Why (Zacks)
Oct-03-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-24 07:00AM	BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome (GlobeNewswire)
Oct-01-24 07:30AM	BioCryst Secures Major US Health Department Influenza Drug Deal (TipRanks)
06:53AM	BioCryst secures $69m contract from US to supply RAPIVAB for influenza (Pharmaceutical Technology)
Sep-30-24 07:00AM	U.S. Government Awards BioCryst $69 Million RAPIVAB (peramivir injection) Contract for Strategic National Stockpile (GlobeNewswire)
Sep-17-24 07:00AM	BioCryst and the pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for ORLADEYO (berotralstat), an Oral, Once-daily Therapy for the Prevention of Hereditary Angioedema Attacks (GlobeNewswire)
Sep-12-24 01:25AM	BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals (GuruFocus.com)
Sep-06-24 02:00AM	BioCryst Presents New ORLADEYO (berotralstat) Data at 7th Bradykinin Symposium (GlobeNewswire)
Sep-05-24 07:00AM	BioCryst Appoints Dr. Donald Fong Chief Medical Officer (GlobeNewswire)
Sep-04-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-22-24 07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-06-24 08:45AM	Rapid Advancements of Innovative Antiviral COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market (GlobeNewswire)
Aug-05-24 01:00PM	BioCryst Pharmaceuticals (BCRX) Q2 2024 Earnings Call Transcript (Motley Fool) +6.98%
09:55AM	Can BioCryst (BCRX) Climb 99.43% to Reach the Level Wall Street Analysts Expect? (Zacks)
08:10AM	BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:06AM	BioCryst: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-02-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-30-24 12:25PM	7 Small-Cap Stocks to Buy for Large-Scale Gains (InvestorPlace)
Jul-29-24 10:00AM	Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-22-24 07:00AM	BioCryst to Report Second Quarter 2024 Financial Results on August 5 (GlobeNewswire)
Jul-18-24 12:00PM	BioCryst (BCRX) Upgraded to Strong Buy: Here's Why (Zacks)
09:55AM	Wall Street Analysts See a 92.57% Upside in BioCryst (BCRX): Can the Stock Really Move This High? (Zacks)
Jul-10-24 04:32AM	ORLADEYO gains approval in Peru for HAE prevention (Pharmaceutical Technology)
Jul-09-24 07:00AM	ORLADEYO (berotralstat) Approved in Peru (GlobeNewswire)
Jul-02-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-04-24 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-24 04:00AM	BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO (berotralstat) Treatment (GlobeNewswire)
May-15-24 01:13PM	BioCryst Pharmaceuticals Shares Rise 20% Following Disclosure of Executive Share Purchases (MT Newswires) +18.66%

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hutson Nancy J	Director	Dec 13 '24	Sale	7.54	7,000	52,780	86,638	Dec 16 04:35 PM
Hutson Nancy J	Director	Dec 13 '24	Proposed Sale	7.51	7,000	52,584		Dec 13 04:23 PM
McKee Amy E	Director	Jun 24 '24	Sale	6.32	8,600	54,352	27,831	Jun 25 04:39 PM
SANDERS MACHELLE	Director	Jun 17 '24	Sale	6.00	4,689	28,134	27,742	Jun 17 04:31 PM
HEGGIE THERESA	Director	Jun 14 '24	Sale	6.11	6,698	40,925	52,852	Jun 14 04:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Biocryst Pharmaceuticals Inc

Upgrade your FINVIZ experience